Takeda raises first-half guidance
This article was originally published in Scrip
Executive Summary
Takedahas raised its consolidated net profit forecast for the first half ended September 30th by ¥20.0 billion ($195.7 million) to ¥70.0 billion. The figure compares with ¥218.0 billion in the same period of last year and reflects the dissolution of the TAP joint venture in the US and costs associated with the acquisition of Millennium Pharmaceuticals. The Japanese firm raised its sales outlook by ¥45.0 billion to ¥805.0 billion (+14%), boosted by Millennium, stronger sales in Japan and exchange rate gains, while operating profit should come in ¥35.0 billion ahead of earlier guidance at ¥85.0 billion (-68%). The company will release an updated full-year forecast at the time of its first-half results on November 4th.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Japan Regulators Kept On Track Despite Pandemic
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports